Sunshine Biopharma, Inc. (SBFM) 10-Year Financial Performance & Capital Metrics

SBFM • • Industrial / General

HealthcareSpecialty & Generic PharmaSpecialty PharmaceuticalsOncology Therapeutics

AboutSunshine Biopharma, Inc., a pharmaceutical and nutritional supplement company, focuses on the research and development of anticancer drugs. The company is developing Adva-27a, a GEM-difluorinated C-glycoside derivative of podophyllotoxin to treat leukemia, lymphoma, testicular, lung, brain, prostate, bladder, colon, ovarian, liver, and other forms of cancers, as well as kills multidrug resistant cancer cells, including pancreatic cancer, breast cancer, small-cell lung cancer, and uterine sarcoma cells; and SBFM-PL4, an anti-coronavirus treatment compound. It also offers Essential 9, a nutritional supplement tablet; and Calcium-Vitamin D supplement under the Essential Calcium-Vitamin D brand name, as well as develops and markets other science-based nutritional supplements. The company has a license agreement with the University of Georgia to advance the development of its anti-coronavirus lead compound, SBFM-PL4. Sunshine Biopharma, Inc. is headquartered in Pointe-Claire, Canada.Show more

Revenue $35M +44.7%
EBITDA -$6M -20.5%
Net Income -$5M -13.9%
EPS (Diluted) -7.32 +97.9%
Gross Margin 30.6% -11.6%
EBITDA Margin -16.02% +16.7%
Operating Margin -16.67% +16.1%
Net Margin -14.72% +21.3%
ROE -22.97% -9.2%
ROIC -42.86% +63.3%
Debt/Equity 0.04 +30.7%
Interest Coverage -662.41 -1800.8%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free
✓High quality earnings: Operating CF exceeds net income
✓Strong 5Y sales CAGR of 340.1%
✓Trading at only 0.0x book value
✓Efficient asset utilization: 1.1x turnover

✗Weaknesses

✗Weak Piotroski F-Score: 1/9
✗Negative free cash flow
✗Weak momentum: RS Rating 17 (bottom 17%)
✗Shares diluted 100.0% in last year
✗Trading more than 30% below 52-week high

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y340.11%

3Y434.46%

TTM19.22%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-71.43%

EPS CAGR

10Y-

5Y-

3Y-

TTM95.12%

ROCE

10Y Avg-347.22%

5Y Avg-124.23%

3Y Avg-88.4%

Latest-25.25%

Peer Comparison

Oncology Therapeutics

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	Debt/Equity
HCMHUTCHMED (China) Limited	2.63B	15.31	69.59	-24.8%	77.53%	37.59%	0.12
SHPHShuttle Pharmaceuticals Holdings, Inc.	2.85M	1.48	-0.00			-7.68%	1.65
BGMSBio Green Med Solution, Inc.	7.01M	1.43	-0.00	-89.76%	-67.15%	-76.65%
SBFMSunshine Biopharma, Inc.	5.99M	1.22	-0.17	44.75%	-17.35%	-24.55%	0.04
RNTXRein Therapeutics Inc.	30.49M	1.16	-0.33			-127.48%
CGEMCullinan Therapeutics, Inc.	629.75M	10.66	-3.43			-48.03%	0.00
ONCBeOne Medicines Ltd.	34.44B	338.29	-55.28	54.96%	1.38%	1.66%	0.32

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	1.71K	0	0	447.2K	21.12K	71.41K	228.43K	4.35M	24.09M	34.87M
Revenue Growth %	-	-1%	-	-	-0.95%	2.38%	2.2%	18.03%	4.54%	0.45%
Cost of Goods Sold+	384.58K	60.73K	6.63K	391.08K	11.05K	25.85K	117.83K	2.65M	15.75M	24.2M
COGS % of Revenue	225.16%	-	-	0.87%	0.52%	0.36%	0.52%	0.61%	0.65%	0.69%
Gross Profit+	-383K	-60.73K	-6.63K	56.12K	10.07K	45.56K	110.6K	1.7M	8.34M	10.67M
Gross Margin %	-224.24%	-	-	0.13%	0.48%	0.64%	0.48%	0.39%	0.35%	0.31%
Gross Profit Growth %	-0.46%	0.84%	0.89%	9.47%	-0.82%	3.52%	1.43%	14.34%	3.91%	0.28%
Operating Expenses+	397.4K	993.11K	857.19K	1.22M	651.71K	622.44K	2.55M	10.37M	13.12M	16.48M
OpEx % of Revenue	232.67%	-	-	2.73%	30.86%	8.72%	11.17%	2.39%	0.54%	0.47%
Selling, General & Admin	769.08K	899.58K	850.56K	1.14M	622.73K	547.42K	1.87M	9.48M	10.83M	14.94M
SG&A % of Revenue	450.28%	-	-	2.54%	29.48%	7.67%	8.17%	2.18%	0.45%	0.43%
Research & Development	8.66K	32.79K	0	12.8K	15.2K	60.95K	672.21K	811.86K	1.86M	933.9K
R&D % of Revenue	5.07%	-	-	0.03%	0.72%	0.85%	2.94%	0.19%	0.08%	0.03%
Other Operating Expenses	4.25K	60.73K	6.63K	14.36K	13.77K	14.07K	12.74K	80.4K	438.88K	610.62K
Operating Income+	-780K	-993.11K	-857.19K	-1.17M	-641.64K	-576.87K	-2.44M	-27M	-4.79M	-5.81M
Operating Margin %	-456.67%	-	-	-2.61%	-30.38%	-8.08%	-10.68%	-6.21%	-0.2%	-0.17%
Operating Income Growth %	0.56%	-0.27%	0.14%	-0.36%	0.45%	0.1%	-3.23%	-10.07%	0.82%	-0.21%
EBITDA+	-775.75K	-932.38K	-850.56K	-1.12M	-627.86K	-562.81K	-2.43M	-26.98M	-4.64M	-5.59M
EBITDA Margin %	-454.19%	-	-	-2.5%	-29.73%	-7.88%	-10.63%	-6.21%	-0.19%	-0.16%
EBITDA Growth %	-76.57%	-0.2%	0.09%	-0.31%	0.44%	0.1%	-3.31%	-10.11%	0.83%	-0.21%
D&A (Non-Cash Add-back)	4.25K	60.73K	6.63K	49.36K	13.77K	14.07K	12.74K	25.16K	149.15K	223.53K
EBIT	-1.35M	-993.11K	-935.41K	-1.99M	-962.15K	-2.62M	-12.11M	-26.47M	-3.97M	-5.36M
Net Interest Income+	-307K	0	0	0	-115.9K	-168.1K	-328.82K	479.24K	674.67K	487.23K
Interest Income	0	0	0	0	0	0	0	518.65K	811.97K	496K
Interest Expense	307.21K	34.73K	104.83K	159.42K	115.9K	168.1K	328.82K	39.41K	137.31K	8.77K
Other Income/Expense	-873K	-2.5M	-183.05K	-990K	-436.42K	-2.21M	-10M	489.61K	674.42K	443.15K
Pretax Income+	-1.65M	-3.5M	-1.04M	-2.16M	-1.08M	-2.78M	-12.44M	-26.51M	-4.11M	-5.37M
Pretax Margin %	-967.8%	-	-	-4.82%	-51.04%	-38.99%	-54.44%	-6.1%	-0.17%	-0.15%
Income Tax+	0	0	1.29K	-41.53K	0	0	0	233.3K	395.17K	-235K
Effective Tax Rate %	1%	1%	1%	1%	1.54%	1%	1%	1.01%	1.1%	0.96%
Net Income+	-1.65M	-3.5M	-1.04M	-2.16M	-1.66M	-2.78M	-12.44M	-26.74M	-4.51M	-5.13M
Net Margin %	-967.8%	-	-	-4.82%	-78.61%	-38.99%	-54.44%	-6.15%	-0.19%	-0.15%
Net Income Growth %	0.15%	-1.12%	0.7%	-1.07%	0.23%	-0.68%	-3.47%	-1.15%	0.83%	-0.14%
Net Income (Continuing)	-1.65M	-3.5M	-1.04M	-2.14M	-1.08M	-2.78M	-12.44M	-26.74M	-4.51M	-5.13M
Discontinued Operations	0	0	0	-18.2K	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-999999.00	-164.63	-23.84	-142.00	-18866.94	-3214.89	-9520.00	-3523.64	-351.36	-7.32
EPS Growth %	-3140.4%	1%	0.86%	-4.96%	-131.87%	0.83%	-1.96%	0.63%	0.9%	0.98%
EPS (Basic)	-999999.00	-164.63	-23.84	-142.00	-18866.94	-3214.89	-9774.32	-3523.64	-351.36	-7.32
Diluted Shares Outstanding	1.53K	3	43.63K	15.23K	1.76K	866	1.31K	7.59K	12.16K	701.75K
Basic Shares Outstanding	1.53K	3	43.63K	15.23K	1.76K	866	1.31K	7.59K	12.16K	701.75K
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	53.91K	58.46K	117.2K	211.51K	65.69K	1.03M	2.2M	27.31M	24.89M	25.97M
Cash & Short-Term Investments	50.8K	57.45K	107.53K	115.22K	48.09K	997.48K	2.05M	21.83M	16.29M	9.69M
Cash Only	50.8K	57.45K	107.53K	115.22K	40.5K	989.89K	2.05M	21.83M	16.29M	9.69M
Short-Term Investments	0	0	0	0	7.59K	7.59K	0	0	0	0
Accounts Receivable	3.11K	0	0	0	430	1.92K	7.8K	1.91M	2.55M	3.87M
Days Sales Outstanding	664.82	-	-	-	7.43	9.79	12.46	160.59	38.67	40.49
Inventory	-3.11K	0	-9.67K	0	15.91K	23.77K	105.65K	3.29M	5.73M	11.28M
Days Inventory Outstanding	-	-	-	-	525.53	335.68	327.27	453.31	132.87	170.08
Other Current Assets	3.11K	1.01K	0	989.57K	0	0	7.59K	0	0	0
Total Non-Current Assets+	619.35K	5.94K	140.29K	935.06K	32.46K	19.53K	7.06K	2.23M	2.46M	4.59M
Property, Plant & Equipment	4.31K	5.94K	60K	269.36K	32.46K	19.53K	7.06K	1.15M	1.01M	1.48M
Fixed Asset Turnover	0.40x	-	-	1.66x	0.65x	3.66x	32.35x	3.76x	23.79x	23.53x
Goodwill	0	0	0	665.7K	0	0	0	0	0	0
Intangible Assets	615.04K	0	0	0	0	0	0	776.86K	1.44M	3.02M
Long-Term Investments	0	0	0	0	0	0	0	0	0	0
Other Non-Current Assets	0	0	80.29K	0	0	0	0	0	0	0
Total Assets+	673.26K	64.4K	257.49K	1.15M	98.14K	1.05M	2.2M	29.55M	27.35M	30.56M
Asset Turnover	0.00x	-	-	0.39x	0.22x	0.07x	0.10x	0.15x	0.88x	1.14x
Asset Growth %	3.69%	-0.9%	3%	3.45%	-0.91%	9.65%	1.11%	12.41%	-0.07%	0.12%
Total Current Liabilities+	1.27M	274.1K	751.14K	912.48K	833.53K	1.05M	91.23K	6.93M	5.55M	6.31M
Accounts Payable	46.59K	28.12K	19.31K	115.83K	96.88K	62.87K	42.94K	2.8M	2.59M	5.54M
Days Payables Outstanding	44.22	169.02	1.06K	108.1	3.2K	887.81	133.02	386.19	59.9	83.59
Short-Term Debt	1.14M	236.97K	722.61K	662.76K	715.57K	964.12K	0	123.03K	0	0
Deferred Revenue (Current)	0	0	0	49.35K	0	0	0	0	0	0
Other Current Liabilities	0	0	0	124.6K	0	0	0	3.63M	2.55M	295.8K
Current Ratio	0.04x	0.21x	0.16x	0.23x	0.08x	0.98x	24.07x	3.94x	4.48x	4.11x
Quick Ratio	0.04x	0.21x	0.17x	0.23x	0.06x	0.95x	22.91x	3.47x	3.45x	2.33x
Cash Conversion Cycle	-	-	-	-	-2.67K	-542.33	206.71	227.72	111.63	126.97
Total Non-Current Liabilities+	1.19M	265.09K	79.71K	289.85K	0	949.01K	1.9M	986.56K	587.76K	744.72K
Long-Term Debt	0	0	79.71K	289.85K	0	949.01K	1.9M	0	0	0
Capital Lease Obligations	0	0	0	0	0	0	0	642.23K	539.03K	744.72K
Deferred Tax Liabilities	0	0	0	0	0	0	0	344.32K	48.73K	0
Other Non-Current Liabilities	0	0	0	0	0	0	0	0	0	0
Total Liabilities	1.27M	274.1K	830.85K	1.2M	833.53K	2M	1.99M	7.92M	6.14M	7.06M
Total Debt+	1.14M	236.97K	802.32K	952.6K	715.57K	1.91M	1.9M	765.26K	657.71K	952.48K
Net Debt	1.09M	179.52K	694.79K	837.39K	675.07K	923.23K	-145.17K	-21.06M	-15.63M	-8.73M
Debt / Equity	-	-	-	-	-	-	8.98x	0.04x	0.03x	0.04x
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-2.54x	-28.59x	-8.18x	-7.32x	-5.54x	-3.43x	-7.42x	-685.10x	-34.85x	-662.41x
Total Equity+	-597.04K	-209.7K	-573.36K	-55.75K	-735.38K	-954.84K	211.66K	21.63M	21.21M	23.5M
Equity Growth %	-0.54%	0.65%	-1.73%	0.9%	-12.19%	-0.3%	1.22%	101.18%	-0.02%	0.11%
Book Value per Share	-390.74	-78969.07	-13.14	-3.66	-416.65	-1102.58	162.07	2849.48	1743.31	33.49
Total Shareholders' Equity	-597.04K	-209.7K	-573.36K	-55.75K	-735.38K	-954.84K	211.66K	21.63M	21.21M	23.5M
Common Stock	198.26K	769.4K	918.74K	85.65K	35.32K	1.73K	2.59K	22.59K	28.02K	2.58K
Retained Earnings	-9.08M	-12.58M	-13.62M	-15.77M	-17.43M	-20.22M	-32.66M	-59.4M	-63.91M	-69.04M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	740	394	504	-3.74K	-2.5K	-2.87K	-23.14K	161.85K	696.11K	-829.96K
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-867.64K	-314.18K	-543.52K	-512.81K	-495.8K	-657.3K	-1.83M	-5.25M	-8.78M	-12.53M
Operating CF Margin %	-507.99%	-	-	-1.15%	-23.47%	-9.2%	-8.01%	-1.21%	-0.36%	-0.36%
Operating CF Growth %	-0.61%	0.64%	-0.73%	0.06%	0.03%	-0.33%	-1.78%	-1.87%	-0.67%	-0.43%
Net Income	-1.65M	-3.5M	-1.04M	-2.16M	-1.66M	-2.78M	-12.44M	-26.74M	-4.51M	-5.13M
Depreciation & Amortization	4.25K	60.73K	6.63K	49.36K	13.77K	14.07K	12.74K	25.16K	149.15K	223.53K
Stock-Based Compensation	116.5K	702.3K	427.4K	676.1K	261.69K	50K	918K	0	0	0
Deferred Taxes	0	0	0	0	-261.69K	-50K	-918K	3.63K	0	0
Other Non-Cash Items	704.53K	3.21M	507.35K	1.54M	1.18M	2.16M	10.7M	18.32M	0	-2.24M
Working Capital Changes	75.74K	-90.99K	-17.26K	54.58K	-30.92K	-42.64K	-108.8K	3.15M	-4.42M	-5.38M
Change in Receivables	0	0	0	-15.45K	-430	-1.49K	-5.88K	-524.49K	-594.14K	-2.34M
Change in Inventory	0	0	0	0	-15.91K	-7.86K	-81.88K	42.98K	-2.37M	-6.01M
Change in Payables	92.31K	-18.96K	-8.81K	61.63K	-18.69K	-35.01K	-18.16K	3.36M	-1.36M	3.98M
Cash from Investing+	-623.6K	-3.44K	-84.01K	-13.91K	-15.28K	-1.19K	0	-14.62M	-656.15K	-2.32M
Capital Expenditures	-623.6K	-3.44K	-3.72K	-18.85K	-860	-1.19K	0	-305K	-82.25K	-2.32M
CapEx % of Revenue	365.11%	-	-	0.04%	0.04%	0.02%	-	0.07%	0%	0.07%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	-618.81K	0	0	0	-14.42K	0	0	33.38K	-573.9K	0
Cash from Financing+	1.4M	324.62K	670.71K	527.64K	442.25K	1.61M	2.9M	39.47M	3.43M	9.29M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	0	126.44K	100.14K	56.69K	25.8K	0	0	11.23M	3.5K	3.56M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-1.49M	-317.62K	-547.24K	-531.66K	-496.66K	-658.49K	-1.83M	-5.55M	-9.56M	-14.85M
FCF Margin %	-873.1%	-	-	-1.19%	-23.51%	-9.22%	-8.01%	-1.28%	-0.4%	-0.43%
FCF Growth %	-1.77%	0.79%	-0.72%	0.03%	0.07%	-0.33%	-1.78%	-2.04%	-0.72%	-0.55%
FCF per Share	-975.95	-119610.09	-12.54	-34.90	-281.39	-760.38	-1400.56	-731.67	-786.12	-21.16
FCF Conversion (FCF/Net Income)	0.52x	0.09x	0.52x	0.24x	0.30x	0.24x	0.15x	0.20x	1.95x	2.44x
Interest Paid	0	0	0	0	0	0	0	0	0	8.13K
Taxes Paid	0	0	0	0	0	0	0	0	0	582.48K

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-	-	-	-	-	-	-5875.41%	-244.92%	-21.04%	-22.97%
Return on Invested Capital (ROIC)	-264.8%	-322.06%	-1409.2%	-193.84%	-133.43%	-	-10489.81%	-6399.49%	-116.91%	-42.86%
Gross Margin	-22423.89%	-	-	12.55%	47.68%	63.8%	48.42%	39.05%	34.61%	30.6%
Net Margin	-96779.86%	-	-	-482.11%	-7860.85%	-3898.74%	-5444.21%	-615.37%	-18.7%	-14.72%
Debt / Equity	-	-	-	-	-	-	8.98x	0.04x	0.03x	0.04x
Interest Coverage	-2.54x	-28.59x	-8.18x	-7.32x	-5.54x	-3.43x	-7.42x	-685.10x	-34.85x	-662.41x
FCF Conversion	0.52x	0.09x	0.52x	0.24x	0.30x	0.24x	0.15x	0.20x	1.95x	2.44x
Revenue Growth	-	-100%	-	-	-95.28%	238.1%	219.88%	1802.59%	454.37%	44.75%

Frequently Asked Questions

Growth & Financials

Sunshine Biopharma, Inc. (SBFM) reported $36.3M in revenue for fiscal year 2024.

Sunshine Biopharma, Inc. (SBFM) grew revenue by 44.7% over the past year. This is strong growth.

Sunshine Biopharma, Inc. (SBFM) reported a net loss of $6.3M for fiscal year 2024.

Dividend & Returns

Sunshine Biopharma, Inc. (SBFM) has a return on equity (ROE) of -23.0%. Negative ROE indicates the company is unprofitable.

Sunshine Biopharma, Inc. (SBFM) had negative free cash flow of $9.5M in fiscal year 2024, likely due to heavy capital investments.

US Stock Screener

...

Sunshine Biopharma, Inc. (SBFM) 10-Year Financial Performance & Capital Metrics

SBFM • • Industrial / General

HealthcareSpecialty & Generic PharmaSpecialty PharmaceuticalsOncology Therapeutics

Revenue $35M +44.7%
EBITDA -$6M -20.5%
Net Income -$5M -13.9%
EPS (Diluted) -7.32 +97.9%
Gross Margin 30.6% -11.6%
EBITDA Margin -16.02% +16.7%
Operating Margin -16.67% +16.1%
Net Margin -14.72% +21.3%
ROE -22.97% -9.2%
ROIC -42.86% +63.3%
Debt/Equity 0.04 +30.7%
Interest Coverage -662.41 -1800.8%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free
✓High quality earnings: Operating CF exceeds net income
✓Strong 5Y sales CAGR of 340.1%
✓Trading at only 0.0x book value
✓Efficient asset utilization: 1.1x turnover

✗Weaknesses

✗Weak Piotroski F-Score: 1/9
✗Negative free cash flow
✗Weak momentum: RS Rating 17 (bottom 17%)
✗Shares diluted 100.0% in last year
✗Trading more than 30% below 52-week high

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y340.11%

3Y434.46%

TTM19.22%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-71.43%

EPS CAGR

10Y-

5Y-

3Y-

TTM95.12%

ROCE

10Y Avg-347.22%

5Y Avg-124.23%

3Y Avg-88.4%

Latest-25.25%

Peer Comparison

Oncology Therapeutics

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	Debt/Equity
HCMHUTCHMED (China) Limited	2.63B	15.31	69.59	-24.8%	77.53%	37.59%	0.12
SHPHShuttle Pharmaceuticals Holdings, Inc.	2.85M	1.48	-0.00			-7.68%	1.65
BGMSBio Green Med Solution, Inc.	7.01M	1.43	-0.00	-89.76%	-67.15%	-76.65%
SBFMSunshine Biopharma, Inc.	5.99M	1.22	-0.17	44.75%	-17.35%	-24.55%	0.04
RNTXRein Therapeutics Inc.	30.49M	1.16	-0.33			-127.48%
CGEMCullinan Therapeutics, Inc.	629.75M	10.66	-3.43			-48.03%	0.00
ONCBeOne Medicines Ltd.	34.44B	338.29	-55.28	54.96%	1.38%	1.66%	0.32

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	1.71K	0	0	447.2K	21.12K	71.41K	228.43K	4.35M	24.09M	34.87M
Revenue Growth %	-	-1%	-	-	-0.95%	2.38%	2.2%	18.03%	4.54%	0.45%
Cost of Goods Sold+	384.58K	60.73K	6.63K	391.08K	11.05K	25.85K	117.83K	2.65M	15.75M	24.2M
COGS % of Revenue	225.16%	-	-	0.87%	0.52%	0.36%	0.52%	0.61%	0.65%	0.69%
Gross Profit+	-383K	-60.73K	-6.63K	56.12K	10.07K	45.56K	110.6K	1.7M	8.34M	10.67M
Gross Margin %	-224.24%	-	-	0.13%	0.48%	0.64%	0.48%	0.39%	0.35%	0.31%
Gross Profit Growth %	-0.46%	0.84%	0.89%	9.47%	-0.82%	3.52%	1.43%	14.34%	3.91%	0.28%
Operating Expenses+	397.4K	993.11K	857.19K	1.22M	651.71K	622.44K	2.55M	10.37M	13.12M	16.48M
OpEx % of Revenue	232.67%	-	-	2.73%	30.86%	8.72%	11.17%	2.39%	0.54%	0.47%
Selling, General & Admin	769.08K	899.58K	850.56K	1.14M	622.73K	547.42K	1.87M	9.48M	10.83M	14.94M
SG&A % of Revenue	450.28%	-	-	2.54%	29.48%	7.67%	8.17%	2.18%	0.45%	0.43%
Research & Development	8.66K	32.79K	0	12.8K	15.2K	60.95K	672.21K	811.86K	1.86M	933.9K
R&D % of Revenue	5.07%	-	-	0.03%	0.72%	0.85%	2.94%	0.19%	0.08%	0.03%
Other Operating Expenses	4.25K	60.73K	6.63K	14.36K	13.77K	14.07K	12.74K	80.4K	438.88K	610.62K
Operating Income+	-780K	-993.11K	-857.19K	-1.17M	-641.64K	-576.87K	-2.44M	-27M	-4.79M	-5.81M
Operating Margin %	-456.67%	-	-	-2.61%	-30.38%	-8.08%	-10.68%	-6.21%	-0.2%	-0.17%
Operating Income Growth %	0.56%	-0.27%	0.14%	-0.36%	0.45%	0.1%	-3.23%	-10.07%	0.82%	-0.21%
EBITDA+	-775.75K	-932.38K	-850.56K	-1.12M	-627.86K	-562.81K	-2.43M	-26.98M	-4.64M	-5.59M
EBITDA Margin %	-454.19%	-	-	-2.5%	-29.73%	-7.88%	-10.63%	-6.21%	-0.19%	-0.16%
EBITDA Growth %	-76.57%	-0.2%	0.09%	-0.31%	0.44%	0.1%	-3.31%	-10.11%	0.83%	-0.21%
D&A (Non-Cash Add-back)	4.25K	60.73K	6.63K	49.36K	13.77K	14.07K	12.74K	25.16K	149.15K	223.53K
EBIT	-1.35M	-993.11K	-935.41K	-1.99M	-962.15K	-2.62M	-12.11M	-26.47M	-3.97M	-5.36M
Net Interest Income+	-307K	0	0	0	-115.9K	-168.1K	-328.82K	479.24K	674.67K	487.23K
Interest Income	0	0	0	0	0	0	0	518.65K	811.97K	496K
Interest Expense	307.21K	34.73K	104.83K	159.42K	115.9K	168.1K	328.82K	39.41K	137.31K	8.77K
Other Income/Expense	-873K	-2.5M	-183.05K	-990K	-436.42K	-2.21M	-10M	489.61K	674.42K	443.15K
Pretax Income+	-1.65M	-3.5M	-1.04M	-2.16M	-1.08M	-2.78M	-12.44M	-26.51M	-4.11M	-5.37M
Pretax Margin %	-967.8%	-	-	-4.82%	-51.04%	-38.99%	-54.44%	-6.1%	-0.17%	-0.15%
Income Tax+	0	0	1.29K	-41.53K	0	0	0	233.3K	395.17K	-235K
Effective Tax Rate %	1%	1%	1%	1%	1.54%	1%	1%	1.01%	1.1%	0.96%
Net Income+	-1.65M	-3.5M	-1.04M	-2.16M	-1.66M	-2.78M	-12.44M	-26.74M	-4.51M	-5.13M
Net Margin %	-967.8%	-	-	-4.82%	-78.61%	-38.99%	-54.44%	-6.15%	-0.19%	-0.15%
Net Income Growth %	0.15%	-1.12%	0.7%	-1.07%	0.23%	-0.68%	-3.47%	-1.15%	0.83%	-0.14%
Net Income (Continuing)	-1.65M	-3.5M	-1.04M	-2.14M	-1.08M	-2.78M	-12.44M	-26.74M	-4.51M	-5.13M
Discontinued Operations	0	0	0	-18.2K	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-999999.00	-164.63	-23.84	-142.00	-18866.94	-3214.89	-9520.00	-3523.64	-351.36	-7.32
EPS Growth %	-3140.4%	1%	0.86%	-4.96%	-131.87%	0.83%	-1.96%	0.63%	0.9%	0.98%
EPS (Basic)	-999999.00	-164.63	-23.84	-142.00	-18866.94	-3214.89	-9774.32	-3523.64	-351.36	-7.32
Diluted Shares Outstanding	1.53K	3	43.63K	15.23K	1.76K	866	1.31K	7.59K	12.16K	701.75K
Basic Shares Outstanding	1.53K	3	43.63K	15.23K	1.76K	866	1.31K	7.59K	12.16K	701.75K
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	53.91K	58.46K	117.2K	211.51K	65.69K	1.03M	2.2M	27.31M	24.89M	25.97M
Cash & Short-Term Investments	50.8K	57.45K	107.53K	115.22K	48.09K	997.48K	2.05M	21.83M	16.29M	9.69M
Cash Only	50.8K	57.45K	107.53K	115.22K	40.5K	989.89K	2.05M	21.83M	16.29M	9.69M
Short-Term Investments	0	0	0	0	7.59K	7.59K	0	0	0	0
Accounts Receivable	3.11K	0	0	0	430	1.92K	7.8K	1.91M	2.55M	3.87M
Days Sales Outstanding	664.82	-	-	-	7.43	9.79	12.46	160.59	38.67	40.49
Inventory	-3.11K	0	-9.67K	0	15.91K	23.77K	105.65K	3.29M	5.73M	11.28M
Days Inventory Outstanding	-	-	-	-	525.53	335.68	327.27	453.31	132.87	170.08
Other Current Assets	3.11K	1.01K	0	989.57K	0	0	7.59K	0	0	0
Total Non-Current Assets+	619.35K	5.94K	140.29K	935.06K	32.46K	19.53K	7.06K	2.23M	2.46M	4.59M
Property, Plant & Equipment	4.31K	5.94K	60K	269.36K	32.46K	19.53K	7.06K	1.15M	1.01M	1.48M
Fixed Asset Turnover	0.40x	-	-	1.66x	0.65x	3.66x	32.35x	3.76x	23.79x	23.53x
Goodwill	0	0	0	665.7K	0	0	0	0	0	0
Intangible Assets	615.04K	0	0	0	0	0	0	776.86K	1.44M	3.02M
Long-Term Investments	0	0	0	0	0	0	0	0	0	0
Other Non-Current Assets	0	0	80.29K	0	0	0	0	0	0	0
Total Assets+	673.26K	64.4K	257.49K	1.15M	98.14K	1.05M	2.2M	29.55M	27.35M	30.56M
Asset Turnover	0.00x	-	-	0.39x	0.22x	0.07x	0.10x	0.15x	0.88x	1.14x
Asset Growth %	3.69%	-0.9%	3%	3.45%	-0.91%	9.65%	1.11%	12.41%	-0.07%	0.12%
Total Current Liabilities+	1.27M	274.1K	751.14K	912.48K	833.53K	1.05M	91.23K	6.93M	5.55M	6.31M
Accounts Payable	46.59K	28.12K	19.31K	115.83K	96.88K	62.87K	42.94K	2.8M	2.59M	5.54M
Days Payables Outstanding	44.22	169.02	1.06K	108.1	3.2K	887.81	133.02	386.19	59.9	83.59
Short-Term Debt	1.14M	236.97K	722.61K	662.76K	715.57K	964.12K	0	123.03K	0	0
Deferred Revenue (Current)	0	0	0	49.35K	0	0	0	0	0	0
Other Current Liabilities	0	0	0	124.6K	0	0	0	3.63M	2.55M	295.8K
Current Ratio	0.04x	0.21x	0.16x	0.23x	0.08x	0.98x	24.07x	3.94x	4.48x	4.11x
Quick Ratio	0.04x	0.21x	0.17x	0.23x	0.06x	0.95x	22.91x	3.47x	3.45x	2.33x
Cash Conversion Cycle	-	-	-	-	-2.67K	-542.33	206.71	227.72	111.63	126.97
Total Non-Current Liabilities+	1.19M	265.09K	79.71K	289.85K	0	949.01K	1.9M	986.56K	587.76K	744.72K
Long-Term Debt	0	0	79.71K	289.85K	0	949.01K	1.9M	0	0	0
Capital Lease Obligations	0	0	0	0	0	0	0	642.23K	539.03K	744.72K
Deferred Tax Liabilities	0	0	0	0	0	0	0	344.32K	48.73K	0
Other Non-Current Liabilities	0	0	0	0	0	0	0	0	0	0
Total Liabilities	1.27M	274.1K	830.85K	1.2M	833.53K	2M	1.99M	7.92M	6.14M	7.06M
Total Debt+	1.14M	236.97K	802.32K	952.6K	715.57K	1.91M	1.9M	765.26K	657.71K	952.48K
Net Debt	1.09M	179.52K	694.79K	837.39K	675.07K	923.23K	-145.17K	-21.06M	-15.63M	-8.73M
Debt / Equity	-	-	-	-	-	-	8.98x	0.04x	0.03x	0.04x
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-2.54x	-28.59x	-8.18x	-7.32x	-5.54x	-3.43x	-7.42x	-685.10x	-34.85x	-662.41x
Total Equity+	-597.04K	-209.7K	-573.36K	-55.75K	-735.38K	-954.84K	211.66K	21.63M	21.21M	23.5M
Equity Growth %	-0.54%	0.65%	-1.73%	0.9%	-12.19%	-0.3%	1.22%	101.18%	-0.02%	0.11%
Book Value per Share	-390.74	-78969.07	-13.14	-3.66	-416.65	-1102.58	162.07	2849.48	1743.31	33.49
Total Shareholders' Equity	-597.04K	-209.7K	-573.36K	-55.75K	-735.38K	-954.84K	211.66K	21.63M	21.21M	23.5M
Common Stock	198.26K	769.4K	918.74K	85.65K	35.32K	1.73K	2.59K	22.59K	28.02K	2.58K
Retained Earnings	-9.08M	-12.58M	-13.62M	-15.77M	-17.43M	-20.22M	-32.66M	-59.4M	-63.91M	-69.04M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	740	394	504	-3.74K	-2.5K	-2.87K	-23.14K	161.85K	696.11K	-829.96K
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-867.64K	-314.18K	-543.52K	-512.81K	-495.8K	-657.3K	-1.83M	-5.25M	-8.78M	-12.53M
Operating CF Margin %	-507.99%	-	-	-1.15%	-23.47%	-9.2%	-8.01%	-1.21%	-0.36%	-0.36%
Operating CF Growth %	-0.61%	0.64%	-0.73%	0.06%	0.03%	-0.33%	-1.78%	-1.87%	-0.67%	-0.43%
Net Income	-1.65M	-3.5M	-1.04M	-2.16M	-1.66M	-2.78M	-12.44M	-26.74M	-4.51M	-5.13M
Depreciation & Amortization	4.25K	60.73K	6.63K	49.36K	13.77K	14.07K	12.74K	25.16K	149.15K	223.53K
Stock-Based Compensation	116.5K	702.3K	427.4K	676.1K	261.69K	50K	918K	0	0	0
Deferred Taxes	0	0	0	0	-261.69K	-50K	-918K	3.63K	0	0
Other Non-Cash Items	704.53K	3.21M	507.35K	1.54M	1.18M	2.16M	10.7M	18.32M	0	-2.24M
Working Capital Changes	75.74K	-90.99K	-17.26K	54.58K	-30.92K	-42.64K	-108.8K	3.15M	-4.42M	-5.38M
Change in Receivables	0	0	0	-15.45K	-430	-1.49K	-5.88K	-524.49K	-594.14K	-2.34M
Change in Inventory	0	0	0	0	-15.91K	-7.86K	-81.88K	42.98K	-2.37M	-6.01M
Change in Payables	92.31K	-18.96K	-8.81K	61.63K	-18.69K	-35.01K	-18.16K	3.36M	-1.36M	3.98M
Cash from Investing+	-623.6K	-3.44K	-84.01K	-13.91K	-15.28K	-1.19K	0	-14.62M	-656.15K	-2.32M
Capital Expenditures	-623.6K	-3.44K	-3.72K	-18.85K	-860	-1.19K	0	-305K	-82.25K	-2.32M
CapEx % of Revenue	365.11%	-	-	0.04%	0.04%	0.02%	-	0.07%	0%	0.07%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	-618.81K	0	0	0	-14.42K	0	0	33.38K	-573.9K	0
Cash from Financing+	1.4M	324.62K	670.71K	527.64K	442.25K	1.61M	2.9M	39.47M	3.43M	9.29M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	0	126.44K	100.14K	56.69K	25.8K	0	0	11.23M	3.5K	3.56M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-1.49M	-317.62K	-547.24K	-531.66K	-496.66K	-658.49K	-1.83M	-5.55M	-9.56M	-14.85M
FCF Margin %	-873.1%	-	-	-1.19%	-23.51%	-9.22%	-8.01%	-1.28%	-0.4%	-0.43%
FCF Growth %	-1.77%	0.79%	-0.72%	0.03%	0.07%	-0.33%	-1.78%	-2.04%	-0.72%	-0.55%
FCF per Share	-975.95	-119610.09	-12.54	-34.90	-281.39	-760.38	-1400.56	-731.67	-786.12	-21.16
FCF Conversion (FCF/Net Income)	0.52x	0.09x	0.52x	0.24x	0.30x	0.24x	0.15x	0.20x	1.95x	2.44x
Interest Paid	0	0	0	0	0	0	0	0	0	8.13K
Taxes Paid	0	0	0	0	0	0	0	0	0	582.48K

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-	-	-	-	-	-	-5875.41%	-244.92%	-21.04%	-22.97%
Return on Invested Capital (ROIC)	-264.8%	-322.06%	-1409.2%	-193.84%	-133.43%	-	-10489.81%	-6399.49%	-116.91%	-42.86%
Gross Margin	-22423.89%	-	-	12.55%	47.68%	63.8%	48.42%	39.05%	34.61%	30.6%
Net Margin	-96779.86%	-	-	-482.11%	-7860.85%	-3898.74%	-5444.21%	-615.37%	-18.7%	-14.72%
Debt / Equity	-	-	-	-	-	-	8.98x	0.04x	0.03x	0.04x
Interest Coverage	-2.54x	-28.59x	-8.18x	-7.32x	-5.54x	-3.43x	-7.42x	-685.10x	-34.85x	-662.41x
FCF Conversion	0.52x	0.09x	0.52x	0.24x	0.30x	0.24x	0.15x	0.20x	1.95x	2.44x
Revenue Growth	-	-100%	-	-	-95.28%	238.1%	219.88%	1802.59%	454.37%	44.75%

Frequently Asked Questions

Growth & Financials

Sunshine Biopharma, Inc. (SBFM) reported $36.3M in revenue for fiscal year 2024.

Sunshine Biopharma, Inc. (SBFM) grew revenue by 44.7% over the past year. This is strong growth.

Sunshine Biopharma, Inc. (SBFM) reported a net loss of $6.3M for fiscal year 2024.

Dividend & Returns

Sunshine Biopharma, Inc. (SBFM) has a return on equity (ROE) of -23.0%. Negative ROE indicates the company is unprofitable.

Sunshine Biopharma, Inc. (SBFM) had negative free cash flow of $9.5M in fiscal year 2024, likely due to heavy capital investments.